Thermal ADA Dissociation for Accurate NAb Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing cell-based functional assays for detecting neutralizing anti-drug antibodies (NAb) are vulnerable to drug interference and serum factors, leading to inaccurate NAb measurement due to irreversible denaturation of NAb by harsh acid treatments.
Innovation Solution
A method involving pre-treatment of samples at high temperatures (60-68°C) to dissociate ADA-drug complexes, followed by isolation using a matrix and retrieval with a buffer, and detection in a cell-based or in vitro assay.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If harsh acid treatment is used to remove drugs and interfering factors from serum samples, then drug interference is reduced and ADA enrichment is improved, but NAb activity is irreversibly denatured leading to underestimated measurement
Solution Approach 1:
The patent changes the chemical parameter from acid treatment to thermal treatment (heat). Instead of using harsh acid that denatures NAb, the method uses controlled heating at 37°C or higher temperatures to dissociate drug-ADA complexes. This parameter change allows effective separation of ADA from drugs while preserving NAb biological activity, resolving the contradiction between removing interference and preserving antibody functionality.
Solution Approach 2:
The patent replaces the chemical mechanism (acid dissociation) with a thermal mechanism (heat-induced dissociation). By substituting the chemical field with thermal field, the method achieves the same separation function without the harmful side effect of NAb denaturation, effectively resolving the technical contradiction.
2Measurement precision
If cell-based functional assays are used to detect NAb, then neutralization activity can be characterized, but the assay is vulnerable to drug interference and serum factors
Solution Approach 1:
The patent applies preliminary thermal treatment to dissociate drug-ADA complexes before performing the cell-based NAb assay. By pre-separating ADA from drugs through heat treatment, the subsequent assay is no longer vulnerable to drug interference or serum factors, as the ADA is now in a form that can be accurately detected without interference. This preliminary action resolves the contradiction by eliminating harmful factors before measurement.
3Quantity of substance
If BEAD method is used to remove circulating drugs from serum, then ADA enrichment is achieved, but the harsh acid causes irreversible denaturing of NAb
Solution Approach 1:
The patent changes the dissociation parameter from acidic pH to elevated temperature. By using thermal energy instead of chemical acidity to break drug-ADA complexes, the method achieves effective ADA enrichment while maintaining NAb structural integrity and biological activity, thus resolving the contradiction between concentration enhancement and stability preservation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Preserves NAb activity by avoiding acid denaturation, enabling accurate detection of ADAs in biological samples, particularly for drugs with lower thermal stability like lulizumab.
Implementation Method 1
pre-treating the sample at a high temperature to dissociate the ADA: drug immune complex in the sample
Data Source
AI summary
In certain embodiments, the present invention provides a method for detecting an anti-drug antibody (ADA) in a sample, comprising: a) pre-treating the sample at a high temperature to dissociate the ADA: drug immune complex in the sample; b) isolating the ADA from the sample by a matrix; c) retrieving the ADA from the matrix using a buffer; and d) detecting the ADA in a cell-based assay or an in vitro assay.